• OPEN AN ACCOUNT
Indian Indices
Nifty
24,008.00 -265.80
(-1.10%)
Sensex
79,454.47 -880.34
( -1.10%)
Bank Nifty
53,595.25 -770.40
( -1.42%)
Nifty IT
35,880.10 -122.35
( -0.34%)
Global Indices
Nasdaq
41,266.30 -123.15
(-0.30%)
Dow Jones
5,680.75 -4.19
(-0.07%)
Hang Seng
37,492.25 563.62
(1.53%)
Nikkei 225
8,554.80 23.19
(0.27%)
Forex
USD-INR
85.39 0.69
(0.81%)
EUR-INR
96.28 0.21
(0.22%)
GBP-INR
113.48 0.52
(0.46%)
JPY-INR
0.59 0.00
(-0.21%)

EQUITY - MARKET SCREENER

P. H. Capital Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
500143
INE160F01013
196.4034532
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
3.88
54.51
EPS(TTM)
Face Value()
Div & Yield %
46.81
10
0.14
 

Sanofi India MD Rodolfo Hrosz resigns
Apr 11,2025

The board of directors accepted Hrosz’s resignation during a meeting held on 9 April and expressed appreciation for his significant contributions during his tenure. Hrosz will cease to be a key managerial personnel, senior management personnel, and a member of board committees at the close of business hours on 30 April 2025.

Further, the board approved Hrosz’s appointment as an additional non-executive director effective 1 May 2025, subject to shareholder approval, upon the recommendation of the nomination and remuneration committee (NRC).

Sanofi India is among the leading multinational companies in the Indian pharmaceutical market. It offers a wide array of medicines for therapy areas such as diabetes, cardiology, thrombosis, the central nervous system, and antihistamines.

The company’s consolidated net profit declined 33.7% to Rs 91.30 crore in Q4 FY25 as against Rs 137.70 crore reported in Q4 FY24. Total revenue from operations grew by 9.7% year on year (YoY) to Rs 514.90 crore in the quarter ended 31 March 2024.

Shares of Sanofi India rose 0.83% to Rs 6,100 on the BSE.